Cipla Ltd.

Cipla has received approval from the US Food and Drug Administration (USFDA) to market the Lanreotide injection in the American market. The Lanreotide injection is used for the treatment of acromegaly and gastroenteropancreatic neuroendocrine tumors. 

This approval is a significant step for its US business and is in line with its aspiration to continue growth in its complex product pipeline and address unmet patient needs.

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients.